Catalyst Pharmaceuticals, Inc. (CPRX) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2025
Loading P/E history...
CPRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) trades at a price-to-earnings ratio of 18.6x, with a stock price of $31.16 and trailing twelve-month earnings per share of $1.68.
The current P/E is roughly in line with its 5-year average of 17.7x. Over the past five years, CPRX's P/E has ranged from a low of 6.8x to a high of 29.5x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CPRX trades at a 17% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
The PEG ratio of 0.99 (P/E divided by 28% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, CPRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CPRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | -Best | +68% | |
| $5B | 8.3Lowest | -Best | +264%Best | |
| $6B | 24.8 | -Best | -34% | |
| $2B | 11.6 | -Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CPRX Historical P/E Data (2019–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $23.34 | $1.68 | 13.9x | -22% |
| FY2025 Q3 | $19.70 | $1.72 | 11.5x | -35% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $21.70 | $1.65 | 13.2x | -26% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $24.25 | $1.57 | 15.4x | -13% |
| FY2024 Q4 | $20.87 | $1.31 | 15.9x | -10% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $19.88 | $1.18 | 16.8x | -5% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $15.49 | $0.54 | 28.7x | +62% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $15.94 | $0.54 | 29.5x | +67% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $16.81 | $0.61 | 27.6x | +56% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $11.69 | $0.52 | 22.5x | +27% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $13.44 | $1.01 | 13.3x | -25% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $16.58 | $0.88 | 18.8x | +6% |
Average P/E for displayed period: 17.7x
See CPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
Is CPRX stock overvalued or undervalued?
CPRX trades at 18.6x P/E, near its 5-year average of 17.7x. The 60th percentile ranking places valuation within normal historical bounds.
How does CPRX's valuation compare to peers?
Catalyst Pharmaceuticals, Inc. P/E of 18.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CPRX's PEG ratio?
CPRX PEG ratio is 0.99. Below 1.0 indicates valuation is supported by earnings growth rate. Historical P/E data spans 2019-2025.